Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Clinical Laboratory Improvement Amendments
standard11 mentionslast seen Nov 2, 2026
A set of regulatory standards that govern all clinical laboratory testing in the U.S., first implemented in 1992.
Relationships 4
- CyPath Lungconforms toClinical Laboratory Improvement Amendments99% confidence6 sources
- MyOme, Inc.conforms toClinical Laboratory Improvement Amendments95% confidence1 source
- artificial intelligenceconforms toClinical Laboratory Improvement Amendments85% confidence1 source
- Centers for Medicare & Medicaid ServicesapprovesClinical Laboratory Improvement Amendments70% confidence1 source
Relationship
CyPath Lungconforms toClinical Laboratory Improvement Amendments
99% confidence6 supporting mentions
Either name opens that entity’s relationships.
Sources 6
- filingSEC EDGAROct 29, 2026bioAffinity Technologies, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CyPath Lung is marketed as a Laboratory Developed Test (LDT), is overseen under the Clinical Laboratory Improvement Amendments (CLIA)
- filingSEC EDGAROct 15, 2026bioAffinity Technologies, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA)
- filingSEC EDGAROct 6, 2026bioAffinity Technologies, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is overseen under the Clinical Laboratory Improvement Amendments (CLIA)
- filingSEC EDGARSep 30, 2026bioAffinity Technologies, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CyPath Lung is marketed as a Laboratory Developed Test (LDT) and LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA)
- filingSEC EDGARSep 22, 2026bioAffinity Technologies, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA)
- filingSEC EDGARSep 17, 2026bioAffinity Technologies, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CyPath Lung is marketed as a Laboratory Developed Test (LDT) and LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA)